Kailera Therapeutics, Inc. (KLRA)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Kailera Therapeutics, Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| RS Roger Song Jefferies | 1,982.3 | $44,005.1 | $39,447.68 | -$4,557.42 | -10.36% |
| HP Hardik Parikh JP Morgan | 1,043.23 | $23,264 | $20,436.85 | -$2,827.15 | -12.15% |
Kailera Therapeutics, Inc. (KLRA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Kailera Therapeutics, Inc. ever had a stock split?
Kailera Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Ronald C. Renaud Jr. CEO | NASDAQ (NGS) Exchange | 482931102 CUSIP |
| US Country | 145 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Kailera Therapeutics is a pioneering clinical-stage biopharmaceutical company that focuses on developing a broad range of innovative therapies aimed at combating obesity and its associated health complications. The company's commitment to addressing this pressing health issue is evident in its diverse pipeline, which includes both injectable and oral formulations intended to facilitate effective chronic weight management. Among its programs, the lead initiative features a dual-action gut hormone receptor agonist, which has shown promising outcomes in early-stage clinical trials, underscoring the potential of Kailera's approach to reshape treatment paradigms in obesity care.
Products and Services
- Dual-Action Gut Hormone Receptor Agonist
This lead therapeutic program is designed to engage multiple pathways involved in weight regulation through the gut. By activating specific hormone receptors, it enhances satiety and reduces appetite, thereby supporting significant weight loss and management. Promising preliminary clinical results highlight its potential role in long-term obesity treatment.
- Injectable Weight Management Solutions
Kailera is developing injectable formulations that leverage cutting-edge biotechnology to create lasting effects on weight control. These solutions are aimed at providing patients with convenient administration options, while effectively addressing both the emotional and physiological aspects of obesity, making them a vital component of the overall therapeutic strategy.
- Oral Weight Management Formulations
In addition to injectables, Kailera is working on advanced oral formulations that offer a user-friendly alternative for patients. These products are designed to provide sustained benefits in weight management, with the ease of daily administration contributing to better adherence and long-term results.
- Personalized Treatment Strategies
Kailera places significant emphasis on personalized medicine. By conducting thorough assessments of individual patient needs, the company aims to tailor its therapeutic interventions, thereby optimizing outcomes and enhancing overall treatment efficacy. This approach is intended to establish the right combination of therapies to meet the unique challenges faced by patients battling obesity.
